by Gus Iversen
, Editor in Chief | March 29, 2021
From the March 2021 issue of HealthCare Business News magazine
As part of our coverage of the National Association for Proton Therapy (NAPT) annual meeting, taking place April 15-16 online, here is a recap of some of the most interesting proton therapy stories we’ve published over the last several months.
For more stories like these, click “Proton Therapy” in the red navigation bar at the top of the screen.
Hackensack Meridian John Theurer Cancer Center affiliates with ProCure NJ
In March, the Hackensack Meridian John Theurer Cancer Center announced a clinical affiliation with ProCure Proton Therapy Center in Somerset, NJ, bringing improved access to proton therapy to its patients.
“At Hackensack Meridian Health, we’ve long provided a wide range of highly precise radiation therapy technologies to meet our patients’ needs, treatments that target tumor tissue while sparing nearby healthy tissue as much as possible,” said Robert C. Garrett, CEO of Hackensack Meridian Health, in a statement. “The affiliation with ProCure NJ will give our adult and pediatric patients direct access to every type of radiation therapy now available for people with cancer.”
ProCure NJ was the first to bring proton therapy to the tri-state region (NY, NJ, CT) and offers advanced pencil beam scanning, which utilizes an ultra-narrow proton beam that deposits a radiation dose more precisely within a tumor.
“Being able to offer the most technologically advanced method to deliver radiation treatment will allow our radiation oncologists to customize the best treatment options for our patients at John Theurer Cancer Center,” said Dr. Andre Goy, the center’s chairman and executive director. “Radiation therapy is undergoing a sort of renaissance with these novel radiation modalities. Our cancer care team has exceptional expertise and extraordinary tools to help patients make the best decisions for their care.”
IBA inks $100 million proton therapy licensing deal in China
Last August, Ion Beam Applications (IBA) signed a strategic licensing deal with China’s CGN Nuclear Technology Development (CGNNT) Co. for the exclusive rights to IBA’s ProteusPLUS technology.
Worth a minimum of 100 million EUR (approximately $118 million USD), the agreement gives CGNNT and its wholly-owned subsidiary CGN Dasheng Electron Accelerator Technology (CGN Dasheng) the right to use ProteusPLUS technology solely in the People’s Republic of China, excluding Hong Kong, Taiwan, and Macau. The deal follows the Chinese government’s decision to expand the number of proton therapy licenses from 10 to 16 in 2020.